Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and <i>in vitro</i> validation.
Overview
- Neurology Department, FAW General Hospital of Jilin Province, Changchun, Jilin, China
Abstract
Background: As a first-line treatment for acute ischemic stroke (AIS), tenecteplase (TNK) can cause adverse effects, such as depression, in AIS patients.
Objective: This study aims to elucidate the TNK target-related pathogenic mechanisms underlying major depressive disorder (MDD) in AIS patients.
Methods: By analyzing six public peripheral blood bulk datasets from AIS and MDD patients using integrative bioinformatics methods (limma, non-negative matrix factorization (NMF), and machine learning), we identified TNK target-associated molecular subgroups and diagnostic models for MDD and AIS patients, respectively. Next, a hub gene involved in the pathogenesis of both MDD and AIS was identified, and its corresponding molecular characteristics were analyzed in the peripheral blood bulk profiles of MDD and AIS patients. In addition, to gain a deeper understanding of the molecular implications of the hub gene involved in the pathogenesis of MDD in AIS, we performed disease ontology (DO) analysis and virtual cell knockout (KO) of the hub gene using public AIS mouse brain single-cell datasets. Furthermore, a deep learning pipeline (DrugReflector) model and molecular docking were used to identify MDD-preventive therapeutic agents for AIS patients based on MDD and AIS public blood bulk data. Finally, the expression pattern of the hub gene was also evaluated in MDD and AIS cell models.
Results: Myeloperoxidase (MPO) can be considered an upregulated TNK target-associated gene involved in the pathogenesis of MDD in AIS patients, and BRD-K11973162 can be considered an MDD-preventive therapeutic candidate for AIS patients after TNK treatment.
Conclusion: Our study is the first to identify MDD-associated diagnostic and therapeutic candidates for AIS patients after TNK treatment, providing a novel strategy for their clinical management.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE58294, at NCBI GEO; found in “Data availability statement”
Data availability statement
Publicly available datasets were analyzed in this study. These data are available in the Gene Expression Omnibus under accession numbers GSE58294 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 6 authors, 5 keywords, 44 references.
Cite
This paper
Wang, Q., Sun, X., Fu, Q., Lv, J., Dong, L., & Yan, Q. (2026). Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and &
BibTeX
@article{wang2026assessm
author = {Wang, Qi and Sun, Xihua and Fu, Qiang and Lv, Jiaqi and Dong, Li and Yan, Qi},
title = {{Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and \&
journal = {Frontiers in neuroscience},
year = {2026},
month = jun,
volume = {20},
pages = {1848128},
publisher = {Frontiers Media SA},
issn = {1662-4548},
doi = {10.3389/
url = {https://
pmid = {42382105},
pmcid = {PMC13315191}
}
RIS
TY - JOUR
AU - Wang, Qi
AU - Sun, Xihua
AU - Fu, Qiang
AU - Lv, Jiaqi
AU - Dong, Li
AU - Yan, Qi
TI - Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and &
T2 - Frontiers in neuroscience
J2 - Front Neurosci
PY - 2026
DA - 2026/
VL - 20
SP - 1848128
SN - 1662-4548
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "Assessment of tenecteplase target-associated pathogenic mechanisms underlying depression in acute ischemic stroke patients: insights from artificial intelligence-driven multi-omics analysis and &
"container-title": "Frontiers in neuroscience",
"author": [
{
"family": "Wang",
"given": "Qi"
},
{
"family": "Sun",
"given": "Xihua"
},
{
"family": "Fu",
"given": "Qiang"
},
{
"family": "Lv",
"given": "Jiaqi"
},
{
"family": "Dong",
"given": "Li"
},
{
"family": "Yan",
"given": "Qi"
}
],
"container-title-short":
"volume": "20",
"page": "1848128",
"DOI": "10.3389/
"PMID": "42382105",
"PMCID": "PMC13315191",
"ISSN": "1662-4548",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
16
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3389/fnagi.2026.1727472
- Artificial intelligence and multi-omics nominate TAZ as an insomnia-related diagnostic and druggable target for Parkinson's disease patients.Journal: Frontiers in aging neuroscienceIn common: genetics / omics, 11 references
- [2] doi:10.3389/fnins.2026.1929767
- Tracing fucosylation and astrocyte-associated pathogenic pattern in major depressive disorder: evidence from machine learning-based multi-omics and clinical validation.Journal: Frontiers in neuroscienceIn common: depression, genetics / omics, 9 references
- [3] doi:10.3389/fnins.2026.1913179
- Decoding astrocytic tryptophan metabolism in the pathogenesis of epilepsy: evidence from artificial intelligence-driven multi-omics and clinical validation.Journal: Frontiers in neuroscienceIn common: genetics / omics, 8 references
- [4] doi:10.3389/fneur.2023.1189746
- Predictive model, miRNA-TF network, related subgroup identification and drug prediction of ischemic stroke complicated with mental disorders based on genes related to gut microbiome.Journal: Frontiers in neurologyIn common: NCBI GEO GSE58294, stroke, 3 references
- [5] doi:10.3389/fgene.2022.1009145
- Expression pattern and clinical value of Key RNA methylation modification regulators in ischemic stroke.Journal: Frontiers in geneticsIn common: NCBI GEO GSE58294, stroke, 3 references
- [6] doi:10.3389/fnins.2026.1950353
- A neuron-distributed DEK integrates ac4C modification and neuroinflammation in pathogenesis of Parkinson disease: evidence from Mendelian randomization, multi-omics and &
lt;i& gt;in vitro& lt;/ i& gt; validation. Journal: Frontiers in neuroscienceIn common: genetics / omics, 5 references - [7] doi:10.18632/aging.205308
- Investigating the ID3/
SLC22A4 as immune-related signatures in ischemic stroke. Journal: AgingIn common: NCBI GEO GSE58294, stroke, 1 reference - [8] doi:10.1186/s12868-026-00997-5
- MEF2A-mediated inhibition of ischemic stroke injury via the PI3K/
AKT pathway: a comprehensive bioinformatics and in vitro study. Journal: BMC neuroscienceIn common: NCBI GEO GSE58294, stroke, genetics / omics - [9] doi:10.1016/j.redox.2022.102547
- Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons.Journal: Redox biologyIn common: NCBI GEO GSE58294, stroke
- [10] doi:10.1186/s40001-025-03477-4 [code]
- Identification of coagulation-related hub genes in ischemic stroke based on bioinformatics integration analysis and investigation of their immune regulatory mechanisms.Journal: European journal of medical researchIn common: stroke, genetics / omics, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
